Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04803786 · ClinicalTrials.gov registry record
A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy
A clinical trial, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- 110
- Enrollment target
NCT04803786: Completed study, sponsored by Jazz Pharmaceuticals.
NCT04803786 is a clinical trial that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 110 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04803786 has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
Study Summary
The rationale for the patient-centric, prospective, observational, non-interventional study design of JZP258-402 is to evaluate the transition experience of participants with narcolepsy treated with oxybate and to examine the impact of transitioning from Xyrem to Xywav in a real-world setting.
Primary Outcome
• Difference between usual Xyrem total nightly dose and initial prescribed total nightly Xywav dose.
Interventions
- DRUG Transition from Xyrem to Xywav
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2021-04-09 |
| Est. Completion | 2022-02-24 |
What the finished NCT04803786 record still lists
NCT04803786 is an observational study that tracks outcomes without assigning an intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Transition from Xyrem to Xywav is the first listed.
NCT04803786 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04803786 about?
NCT04803786 is a clinical study titled "A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy". The rationale for the patient-centric, prospective, observational, non-interventional study design of JZP258-402 is to evaluate the transition experience of participants with narcolepsy treated with oxybate and to examine the impact of transitioning from Xyrem to Xywav in a real-world setting.
What is the current status of trial NCT04803786?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2021-04-09. Estimated completion is 2022-02-24.
What interventions are being tested in trial NCT04803786?
The interventions under investigation include: Transition from Xyrem to Xywav (DRUG).
Who is sponsoring clinical trial NCT04803786?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI